RxDoctor Payments Data

Jessica Richardson, APRN

Nurse Practitioner · Wildwood, FLNPI 1013491224

Payments from drug & device makers

$3,095in general payments, 2019–2025

Across 130 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$512
  • Merz North America, Inc.$439
  • Merck$400
  • Johnson & Johnson$257
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$232
  • Impulse Dynamics (USA) Inc.$229
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,081100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,095 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$47,783
Medicare patients
338
Services billed
516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$108,940
EntrestoSacubitril/Valsartan80$107,040
XareltoRivaroxaban88$102,535
JardianceEmpagliflozin28$32,082
FarxigaDapagliflozin Propanediol33$31,048
Repatha SureclickEvolocumab38$27,309
Ranolazine ErRanolazine33$7,154
Dabigatran EtexilateDabigatran Etexilate Mesylate12$4,890
Metoprolol Succinate173$4,088
Nebivolol Hcl34$3,862
Amiodarone Hcl30$2,656
Isosorbide Mononitrate ErIsosorbide Mononitrate126$1,877
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$1,536
Amlodipine Besylate127$955
Rosuvastatin Calcium61$746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$512$108,94091 claims
NovartisEntresto$150$107,04080 claims
Johnson & JohnsonXarelto$257$102,53588 claims
Boehringer IngelheimJardiance$152$32,08228 claims
AstraZenecaFarxiga$158$31,04833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Wildwood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →